New Haven, Conn. — A team of Yale Cancer Center investigators led by Roy S. Herbst, MD, PhD, has been awarded the 2018 Team Science Award from the Association for Clinical and Translational Science (ACTS) for its pioneering work in advancing our understanding of Immunotherapy. The ACTS team science award recognizes the efforts of interdisciplinary teams in the translation of research discoveries into clinical applications and eventually widespread clinical practice. Proactive interaction between academic and industry researchers is particularly crucial to continue progress and accelerate drug development.
Award winners will be honored in Washington, D.C., April 19, 2018 at Translational Science 2018, the joint annual meeting of the Association for Clinical and Translational Science (ACTS), American Federation for Medical Research (AFMR), Association of American Medical Colleges (AAMC) and Clinical Research Forum.
Yale Cancer Center (YCC) is one of only 49 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in southern New England. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.